{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:19:15Z","timestamp":1779938355071,"version":"3.53.1"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2683,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effect of selegiline (<jats:sc>L<\/jats:sc>\u2010deprenyl) on plasma catecholamines, clinical response, and drug tolerability was studied in 13 patients with Parkinson's disease (PD) treated with <jats:sc>L<\/jats:sc>\u2010Dopa\/benserazide and entacapone, a peripheral catechol\u2010<jats:italic>O<\/jats:italic>\u2010methyltransferase (COMT) inhibitor, in a placebo\u2010controlled double\u2010blind study. An <jats:sc>L<\/jats:sc>\u2010Dopa test was performed on 3 study days. The first study day was with <jats:sc>L<\/jats:sc>\u2010Dopa\/benserazide only (control), the second after 14 days of treatment with 200 mg entacapone taken concomitantly with <jats:sc>L<\/jats:sc>\u2010Dopa\/benserazide in combination with either selegiline (10 mg daily) or placebo. After a 2\u2010week washout period, selegiline and placebo treatments were switched, and the third study day was after 14 days of treatment. During the study days, clinical response was evaluated at 30\u2010min intervals for 6 h, by using the motor score of the Unified Parkinson's Disease Rating Scale (UPDRS). In addition, repeated blood pressure measurements were made, and plasma samples were taken for analysis of <jats:sc>L<\/jats:sc>\u2010Dopa, 3\u2010<jats:italic>O<\/jats:italic>\u2010methyldopa (3\u2010OMD), dihydroxyphenyl acetic acid (DOPAC), homovanillic acid (HVA), dopamine, nor\u2010adrenaline, and 3\u2010methoxy\u20104\u2010hydroxyphenylethylene glycol (MHPG). Monoamine oxidase B (MAO\u2010B) and COMT enzyme activities were measured from platelets and erythrocytes, respectively. Entacapone improved the clinical response to <jats:sc>L<\/jats:sc>\u2010Dopa during both selegiline and placebo (p &lt; 0.001) treatments. The improvement was more marked during combined selegiline and entacapone treatment than with entacapone alone (p &lt; 0.01). Entacapone significantly increased plasma <jats:sc>L<\/jats:sc>\u2010Dopa and DOPAC levels and decreased plasma 3\u2010OMD and MHPG levels both with selegiline and placebo. Selegiline partially inhibited the entacapone\u2010induced increase of plasma DOPAC. Plasma dopamine and noradrenaline levels did not change. Entacapone decreased erythrocyte COMT activity by &gt;35% (p &lt; 0.001), and platelet MAO\u2010B activity was almost completely inhibited by selegiline (p &lt; 0.001). One patient withdrew because of diarrhea, dizziness, and loss of sleep when receiving selegiline treatment. Otherwise no differences in adverse events, mean daily blood pressures, or other safety parameters were observed between selegiline and placebo treatments. Our results suggest that entacapone can be safely administered together with <jats:sc>L<\/jats:sc>\u2010Dopa and selegiline in patients with PD, although further studies with larger number of patients and longer treatment periods are necessary to confirm this finding.<\/jats:p>","DOI":"10.1002\/mds.870120404","type":"journal-article","created":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T20:28:13Z","timestamp":1117312093000},"page":"497-505","source":"Crossref","is-referenced-by-count":40,"title":["Simultaneous MAO\u2010B and COMT inhibition in <scp>L<\/scp>\u2010dopa\u2010treated patients with parkinson's disease"],"prefix":"10.1002","volume":"12","author":[{"given":"Jukka","family":"Lyytinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Kaakkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Ahtila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Tuomainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Ter\u00e4v\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"issue":"1","key":"e_1_2_1_2_2","first-page":"11","article-title":"Motor complications associated with chronic levodopa therapy in Parkinson's disease","volume":"11","author":"Obeso JA","year":"1989","journal-title":"Neurology"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01664007"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198403000-00002"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198713030-00002"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90614-0"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199108000-00005"},{"key":"e_1_2_1_8_2","first-page":"211","article-title":"Interaction of the COMT inhibitor entacapone with l\u2010Dopa in MPTP treated common marmosets [Abstract]","volume":"20","author":"Jenner P","year":"1993","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199304000-00007"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.913"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.1.77"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.1.36"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280305"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212004"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2502843"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1109"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315512"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00394.x"},{"key":"e_1_2_1_19_2","first-page":"582","article-title":"COMT inhibition by high\u2010dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise","volume":"11","author":"Illi A","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_1_21_2","first-page":"153","volume-title":"Recent developments in Parkinson's disease: 2","author":"Fahn S","year":"1987"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(91)80140-5"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(92)80085-2"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(83)90442-6"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)00433-6"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1993.1026"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199002000-00003"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(89)90169-X"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05357.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02259539"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870120404","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870120404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:15:12Z","timestamp":1760969712000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870120404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1002\/mds.870120404"],"URL":"https:\/\/doi.org\/10.1002\/mds.870120404","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}